ARWR — Arrowhead Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $9.52bn
- $9.26bn
- $829.45m
- 62
- 15
- 100
- 62
Annual income statement for Arrowhead Pharmaceuticals, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 138 | 243 | 241 | 3.55 | 829 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 287 | 422 | 446 | 605 | 731 |
| Operating Profit | -149 | -179 | -205 | -601 | 98.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -141 | -173 | -206 | -612 | 51.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -141 | -176 | -209 | -610 | 30.1 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -141 | -176 | -205 | -599 | -1.63 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -141 | -176 | -205 | -599 | -1.63 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.36 | -1.67 | -1.92 | -5 | -0.012 |